Subject(s)
Humans , Male , Female , Psoriasis/drug therapy , Psoriasis/therapy , Interleukin-17 , Interleukin-23 , Patients/statistics & numerical data , Dermatology , Skin Diseases , Biological ProductsSubject(s)
Humans , Male , Female , Psoriasis/drug therapy , Psoriasis/therapy , Interleukin-17 , Interleukin-23 , Patients/statistics & numerical data , Dermatology , Skin Diseases , Biological ProductsABSTRACT
No disponible
Subject(s)
Humans , Evidence-Based Medicine , Research Design , Clinical Trials as TopicABSTRACT
Objetivo Identificar productores de información farmacoterapéutica no publicada en revistas biomédicas orientada a la evaluación y posicionamiento terapéutico de los medicamentos y desarrollar un buscador para el acceso a dicha información. Métodos Recopilación de sitios web productores de información sobre uso racional de los medicamentos e independientes de los intereses promocionales. Páginas web de acceso libre, y en castellano, gallego, catalán o inglés. Diseño de un buscador mediante aplicación «búsqueda personalizada» de Google. Resultados Se han recopilado 159 direcciones de Internet y se han clasificado en 9 etiquetas. El buscador, denominado AlquimiA y accesible desde http://www.elcomprimido.com/FARHSD/AlquimiA.htm, permite recuperar información de las fuentes seleccionadas. Conclusiones Se han identificado las principales fuentes de información farmacoterapéutica no publicada en revistas biomédicas. El buscador constituye una herramienta útil para la búsqueda y acceso a las publicaciones de «evidencia gris» en Internet (AU)
Objective To identify publishers of pharmacotherapeutic information not found in biomedical journals that focuses on evaluating and providing advice on medicines and to develop a search engine to access this information. Methods Compiling web sites that publish information on the rational use of medicines and have no commercial interests. Free-access web sites in Spanish, Galician, Catalan or English. Designing a search engine using the Google custom search application. Results Overall 159 Internet addresses were compiled and were classified into 9 labels. We were able to recover the information from the selected sources using a search engine, which is called AlquimiA and available from http://www.elcomprimido.com/FARHSD/AlquimiA.htmConclusionsThe main sources of pharmacotherapeutic information not published in biomedical journals were identified. The search engine is a useful tool for searching and accessing grey literature on the Internet (AU)
Subject(s)
Drug Information Services/organization & administration , Consumer Health Information/organization & administration , Drug Evaluation/trends , Information Storage and Retrieval , Webcasts as TopicABSTRACT
OBJECTIVE: To identify publishers of pharmacotherapeutic information not found in biomedical journals that focuses on evaluating and providing advice on medicines and to develop a search engine to access this information. METHODS: Compiling web sites that publish information on the rational use of medicines and have no commercial interests. Free-access web sites in Spanish, Galician, Catalan or English. Designing a search engine using the Google "custom search" application. RESULTS: Overall 159 internet addresses were compiled and were classified into 9 labels. We were able to recover the information from the selected sources using a search engine, which is called "AlquimiA" and available from http://www.elcomprimido.com/FARHSD/AlquimiA.htm. CONCLUSIONS: The main sources of pharmacotherapeutic information not published in biomedical journals were identified. The search engine is a useful tool for searching and accessing "grey literature" on the internet.
Subject(s)
Clinical Pharmacy Information Systems , Internet , Publishing , Search Engine , Periodicals as TopicABSTRACT
No disponible
Subject(s)
Humans , Female , Middle Aged , Metoclopramide/adverse effects , Tryptophan/adverse effects , Attention Deficit Disorder with Hyperactivity/chemically induced , Serotonin Syndrome/chemically induced , Serotonin Syndrome/complications , Magnetic Resonance Imaging/methods , /methods , Electroencephalography , Selective Serotonin Reuptake Inhibitors/adverse effects , Rhabdomyolysis/complicationsABSTRACT
OBJECTIVE: To assess the impact of pharmaceutical intervention on the use of sequential therapy (ST) with fluoroquinolones. METHODS: A prospective comparative study of pharmaceutical intervention in two stages: observational stage and intervention stage for ST promotion. RESULTS: In all, 250 patients receiving intravenous therapy with fluoroquinolones (113 with levofloxacin and 137 with ciprofloxacin) were studied, with 76 and 70 patients, respectively, being eligible for a pharmaceutical intervention program to promote ST. Pharmaceutical intervention showed a decreased duration of intravenous therapy and increased duration of oral therapy for both drugs, as well as decreased medication-related costs, all in a statistically significant manner. DISCUSSION: ST promotion provides an opportunity to expand the role of hospital pharmacists and to optimize fluoroquinolone-based therapy, which results in decreased intravenous treatments and provides a more cost-effective option.
Subject(s)
Fluoroquinolones/administration & dosage , Pharmacy Service, Hospital/methods , Administration, Oral , Aged , Anti-Infective Agents/administration & dosage , Anti-Infective Agents/economics , Drug Administration Schedule , Female , Fluoroquinolones/economics , Humans , Injections, Intravenous , Male , Middle Aged , Pharmacy Service, Hospital/economics , Pharmacy Service, Hospital/statistics & numerical data , Prospective StudiesABSTRACT
OBJECTIVE: To clinically assess effectiveness of therapeutic interchange from glibenclamide to gliclazide in the hospital setting. METHODS: An open-label prospective, randomized study with two groups of patients: a reference group (patients still receiving their previous outpatient regimen of glibenclamide) and an interchange group (patients with gliclazide substituted for glibenclamide according to a hospital-approved interchange protocol). The efficacy endpoint used was blood glucose at 3 and 6 days post-intervention. A patient with blood glucose < 200 mg/L was considered clinically controlled, and blood glucose changes < or > 30 mg/dL were considered significant. RESULTS: One hundred and sixteen patients were randomized. Blood glucose on the day before the intervention was 177.9 mg/dL +/- 63.4 in the reference group versus 171.3 mg/dL +/- 52.1 in the interchange group (p = 0.92). Mean blood glucose during the first 3 days post-intervention was 156.1 mg/dL +/- 47.5 and 177.7 mg/dL +/- 36.0 (p = 0.14) in the reference and interchange groups, respectively; and mean values for the first 6 days post-intervention were 142.1 mg/dL +/- 36.0 and 172.8 mg/dL +/- 28.2, respectively (p = 0.01). The overall analysis of blood glucose levels showed a better control in the reference group versus baseline values, which was not seen in the interchange group, where blood glucose remained stable and similar to baseline. In no case were 3-day and 6-day blood glucose mean levels above 200 mg/dL, which may be considered acceptable within the hospital setting. CONCLUSIONS: Therapeutic interchange may be safely performed with no clinical impairment, but better controls were achieved in the reference group.
